Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.53 |
| ▸ | KLK5 | Q9Y337 | 3/20 | 0.47 |
| ▸ | APP | P05067 | 4/20 | 0.45 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | ACE | P12821 | 2/20 | 0.44 |
| ▸ | CTSS | P25774 | 2/20 | 0.43 |
| ▸ | CTSL | P07711 | 2/20 | 0.43 |
| ▸ | CTSB | P07858 | 1/20 | 0.43 |
| ▸ | CTSK | P43235 | 1/20 | 0.43 |
| ▸ | SYK | P43405 | 1/20 | 0.43 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5416338 | 0.90 | ATM (0.51) | ATMKLK5APPSIRT5L3MBTL1 | |
| SCHEMBL5408458 | 0.90 | ATM (0.51) | ATMKLK5APPSIRT5L3MBTL1 | |
| SCHEMBL5404753 | 0.83 | CTSK (0.42) | KLK5CTSSCTSLCTSK | |
| SCHEMBL5406367 | 0.83 | CTSK (0.42) | KLK5CTSSCTSLCTSK | |
| SCHEMBL5403799 | 0.83 | CTSS (0.53) | ATMKLK5L3MBTL1ACECTSS | |
| SCHEMBL5411636 | 0.81 | CA1 (0.40) | CTSSCTSLCTSBCTSK | |
| SCHEMBL5409971 | 0.80 | ATM (0.58) | ATMKLK5APPSIRT5ACE | |
| SCHEMBL5406797 | 0.79 | ATM (0.43) | ATMKLK5L3MBTL1ACECTSS | |
| SCHEMBL5404145 | 0.79 | ATM (0.43) | ATMKLK5L3MBTL1ACECTSS | |
| SCHEMBL489489 | 0.77 | ATM (0.70) | ATMKLK5APPACECTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7202269-B2 | GlyT2 modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-04-10 | — | — | US | disclosed |
| US-20050119245-A1 | GlyT2 modulators | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-06-02 | — | — | US | disclosed |
| WO-2005044810-A1 | GLYT2 MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050119245-A1 | GlyT2 modulators | GLRB, GLRA1, GLRA2 | ATM 2145/4885KLK5 4382/4885APP 1184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.